Slide 1: The Leader in Next Generation ADC Payloads
THE LEADER IN NEXT GENERATION ADC PAYLOADS Andreas Pahl • Bio€quity 2025 • 13 May 2025
Slide 2: Safe Harbor
Safe Harbor FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, competition from other biopharmaceutical, chemical and relating to the Company’s business, which can be identified by the pharmaceutical companies, environmental, health and safety matters, use of
Slide 3: ATAC - Innovative ADCs With Amanitin Payload
ATAC - Innovative ADCs With Amanitin Payload Payload: α-Amanitin HDP-101 – anti-BCMA • Identified in Amanita phalloides mushroom • Completely novel mode of action (MOA): • Inhibition of RNA Polymerase II • Kills dormant/non-dividing tumor cells • Circumvents resistance via new mechanism • Synthetic
Slide 4: The Payload Makes the Difference
The Payload Makes the Difference Breast Cancer Model (JIMT-1 Xenograft) is resistant to Kadcyla® and Enhertu® Same antibody (Trastuzumab), different payload JIMT-1 (amanitin vs. topoisomerase inhibitor) xenograft PBS (control) Mean tumor volume [mm3] Enhertu® (20 mg/kg) Control Enhertu® treatment Tr
Slide 5: Heidelberg Pharma's Proprietary Amanitin Payload Technology to Generate a Disruptive New Class of ADCs
Heidelberg Pharma's Proprietary Amanitin Payload Technology to Generate a Disruptive New Class of ADCs Novel MOA Biomarker for Stratification Single Player Overcoming resistance of High-risk Patients M-Protein & IgG Change Over Standard Risk OS - 110 months 20 11 Cycles of HDP-101 Levels (g/dL) 15 C
Slide 6: HDP-101 – Phase I Preliminary Efficacy Data
HDP-101 – Phase I Preliminary Efficacy Data * Complete Response * * Readout: November 2024 Treatment duration (days) Progressive disease (PD) Partial response (PR) Very good partial response (VGPR) End of treatment Minimal response (MR) Stable disease (SD) Complete response (CR) * Adverse Event, mos
Slide 7: Case Summary: Cohort 5 Complete Response
Case Summary: Cohort 5 Complete Response 20 70 Year Old Patient with Stage II IgG-Ϗ Myeloma Since 2002 M-Protein IgG • 9 prior lines of therapies including transplant, IMiDs, PIs, and 15 Daratumumab Levels (g/dL) • Last 3 treatment regimens & response: 10 7th line: BCMA CAR-T (Aug-2018) VGPR 5 8th l
Slide 8: HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma
HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma CX RP2D tbc Phase I: Dose Escalation C8 Q1W split Key Eligibility Criteria dosing Q3W intravenous dosing, BLRM Design 140 µg/kg Split 1st dose & C8 premed*, then Q3W • Prior SCT or transplant ineligible Objectives Q1W split C7
Slide 9: Cohort 7 Summary and Cohort 8 Outlook
Cohort 7 Summary and Cohort 8 Outlook Cohort 7 has been completed • The dose level is at maximum escalation according to study protocol using dose distribution • Weekly dose (amendment planned to allow switch between weekly and 3 So far, 34 heavily treated patients weekly dosing) received HDP-101. •
Slide 10: Transaction with HealthCare Royalty, amended March 2025
Transaction with HealthCare Royalty, amended March 2025 Partial monetization of royalty stream for TLX250-CDx in the field of diagnostic use Key terms of the agreement between Heidelberg Pharma and HealthCare Royalty: • USD 25m upfront payment received in March 2024, no repayment obligation in case
Slide 11: Finances – as of February 28, 2025
Finances – as of February 28, 2025 Total Assets (including cash) EUR 52.8m Healthcare Royalty agreement additional USD 70m available upon drug approval* Equity EUR 25.1m Common shares 46.6m Major Shareholders dievini & affiliated parties 44%, Huadong Medicine 35% Cash as of February 28, 2025 - Expec
Slide 12: ADC Program Pipeline: Multiple Potential Value Drivers
ADC Program Pipeline: Multiple Potential Value Drivers Product Target Indication Research Preclinic Phase I Phase II Phase III Approval Partner HDP-101 BCMA Multiple Myeloma ------------------------------------------------------------------------------------------ Huadong (China+) Potential for auto
Slide 13: Corporate Highlights
Corporate Highlights Proprietary Payloads, Wholly-owned Assets & Partnered ADCs Lead ADC Program HDP-101 (BCMA-ATAC): Technology and Asset Partnerships Maximize • Proprietary Amanitin Payload (patent exclusivity) Value of Pipeline • Overcome resistance due to new MOA • HDP-101 Phase I/IIa ongoing in
Slide 14: Thank You for Your Attention!
THANK YOU FOR YOUR Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 ATTENTION! investors@hdpharma.com investors@hdpharma.com www.heidelberg-pharma.com www.heidelberg-pharma.com